# Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
Canonical URL: https://biopharmsignal.com/news/DSGN/design-therapeutics-announces-plans-to-initiate-patient-dosing-of-dt-818-in-myotonic-dystrophy-type-1-dm1-in-the-first-half-of-2026-and-reports-third-quarter-2025-financial-results
Ticker: DSGN
Company: Design Therapeutics
Source: Design Therapeutics
Published: 2025-11-05 21:01 EST
Original Source URL: https://investors.designtx.com
## Summary

Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1)  Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial Corneal Dystrophy  (FECD) Ongoing Cash and Securities of $206.0 Million as of Third Quarter 2025

## Article Body
Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1)  Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial Corneal Dystrophy  (FECD) Ongoing Cash and Securities of $206.0 Million as of Third Quarter 2025
## Recent Company News
- 2026-06-30 12:00 EST — [Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1](https://biopharmsignal.com/news/DSGN/design-therapeutics-announces-initiation-of-patient-dosing-in-phase-1-multiple-a-1d18e89a) — Source: Design Therapeutics
- 2026-05-28 12:00 EST — [Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/DSGN/design-therapeutics-to-participate-in-2026-jefferies-global-healthcare-conference) — Source: Design Therapeutics
- 2026-05-18 11:00 EST — [Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia](https://biopharmsignal.com/news/DSGN/design-therapeutics-announces-four-week-iv-data-from-the-restore-fa-trial-of-dt-216p2-demonstrating-clinical-improvements-and-comprehensive-biomarker-activity-in-friedreich-ataxia) — Source: Design Therapeutics
- 2026-05-17 20:00 EST — [Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026](https://biopharmsignal.com/news/DSGN/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreich-s-ataxia-on-monday-may-18-2026) — Source: Design Therapeutics
- 2026-04-28 20:01 EST — [Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates](https://biopharmsignal.com/news/DSGN/design-therapeutics-announces-first-quarter-2026-financial-results-and-recent-business-updates) — Source: Design Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)